iiinova — where your digital self keeps evolving

Laura Sena

@laurasenamd.bsky.social

357 followers 733 following 7 posts

Physician-scientist and prostate cancer medical oncologist at Johns Hopkins

Posts Replies Media

Reposted by Laura Sena

🧬Jacob L Steenwyk @jlsteenwyk.bsky.social · 29/01/2026

Researchers developed SVCFit, a tool that tracks how prostate cancer evolves under treatment by analyzing large chromosomal rearrangements often missed by standard approaches. www.biorxiv.org/content/10.1101/202…

Figure from: Longitudinal structural variant phylogenies define tumor evolution under therapeutic selection press

142

Laura Sena @laurasenamd.bsky.social · 26/01/2026

Several exciting findings here, including that 3 mos of BAT can markedly change the clonal composition of metastatic prostate cancer in association with acquired therapy resistance. Very fun to work with @rachelkarchin.bsky.social and team! @pcf-science.bsky.social @hopkinsmedicine.bsky.social

030

Laura Sena @laurasenamd.bsky.social · 22/05/2025

We are excited to open a clinical trial to assess how metabolic changes induced by water-only fasting affects the immune response to prostate cancer. Spread the word – I’m happy to discuss with any interested candidates. clinicaltrials.gov/study/NCT068...

clinicaltrials.gov

ClinicalTrials.gov

020

Reposted by Laura Sena

Josh Lang @joshlangmd.bsky.social · 06/02/2025

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the Dr. Marina Sharifi and Dr. Jamie Sperger and funded by Funded by PCF, NCI, DOD @theaacr.bsky.social urldefense.com/v3/__https:/...

172

Reposted by Laura Sena

American Association for Cancer Research (AACR) @theaacr.bsky.social · 18/02/2025

The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement: buff.ly/4gRXNB8

38258

Reposted by Laura Sena

Brendan Manning @bdmanning.bsky.social · 23/12/2024

But…..ok, ok, I’m convinced. Elegant and definitive. www.science.org/doi/10.1126/...

science.org

Metformin targets mitochondrial complex I to lower blood glucose levels

Acute oral metformin administration lowers blood glucose levels by targeting mitochondrial complex I.

1339

Laura Sena @laurasenamd.bsky.social · 13/12/2024

174

Reposted by Laura Sena

David J. Einstein @davidjeinstein.bsky.social · 09/12/2024

Fascinating and well written! Reminiscent of a patient from our rapid autopsy cohort with targetable truncal driver but remarkable “dead-end” CNA-quiet subclones in the primary that fail to metastasize despite aggressive histology. pubmed.ncbi.nlm.nih.gov/34568716/

pubmed.ncbi.nlm.nih.gov

Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors - PubMed

These findings indicate that truncal alterations identified in primary PC can drive advanced mCRPC, even in the presence of additional strong oncogenic drivers (ie, <i>RB1</i> and <i>BRCA2</i> loss), ...

051

Laura Sena @laurasenamd.bsky.social · 09/12/2024

Happy to share an educational case that demonstrates that selection can drive acquired therapy resistance in metastatic prostate cancer rdcu.be/d15Ph Wonderful collab with @rachelkarchin.bsky.social @davidesanin.bsky.social

rdcu.be

Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer

npj Precision Oncology - Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer

062

Laura Sena @laurasenamd.bsky.social · 07/12/2024

Thanks for visiting and teaching us amazing science Nima!!

142